Tivozanib Approval Status

  • FDA approved: No
  • Generic name: tivozanib
  • Company: AVEO Oncology and Astellas Pharma Inc.
  • Treatment for: Renal Cell Carcinoma

Tivozanib is an oral, once-daily, investigational tyrosine kinase inhibitor in development for the treatment of advanced renal cell carcinoma.

FDA Approval Status for tivozanib

DateArticle
Feb 15, 2014AVEO and Astellas to End Worldwide Collaboration & License Agreement for Tivozanib
Dec 16, 2013AVEO Provides Update on Interim Analysis from Tivozanib Trial in Colorectal Cancer
Jun 10, 2013AVEO Announces Complete Response Letter Received for Tivozanib New Drug Application in Renal Cell Carcinoma
May  2, 2013AVEO and Astellas Report FDA Oncologic Drug Advisory Committee Votes Tivozanib Application Did Not Demonstrate Favorable Benefit-to-Risk Evaluation in Treatment of Advanced Renal Cell Carcinoma
Feb 27, 2013AVEO and Astellas Announce FDA Advisory Committee To Review Tivozanib for the Treatment of Advanced Renal Cell Carcinoma
Nov 28, 2012AVEO and Astellas Announce FDA Acceptance of NDA Filing for Tivozanib for the Treatment of Advanced Renal Cell Carcinoma
Sep 28, 2012AVEO and Astellas Announce Submission of New Drug Application for Tivozanib for the Treatment of Advanced Renal Cell Carcinoma

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide
(web1)